AEZ. AEterna Zentaris Inc.

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that , Chief Executive Officer of Aeterna, will present at the taking place January 11-14, 2021.

The presentation will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and will be accessible on the page in the section of the Company’s website ().

For more information about the event, please visit the conference website .

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™ through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.

Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Asia and the rest of the world, in addition to other non-strategic assets to monetize their value. For more information, please visit and connect with the Company on , and .



Investor Contact:



Jenene Thomas

JTC Team

T (US): +1 (833) 475-8247

E:



EN
05/01/2021

Underlying

AEZ.AEterna Zentaris Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AEterna Zentaris Inc.

 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its board of directors and as Chair of the Company’s Audit Committee, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today. Mr. Labbé has more...

October 1, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Manage...

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided an update on the progress of its merger integration with Ceapro Inc. (“Ceapro”), including planned changes to its management team and advancements across its current ...

September 23, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-T...

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of macimorelin confirmed in the pediatric population TORONTO, ONTARIO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commerci...

August 27, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results                 Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash         TORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today report...

August 13, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company’s name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August 6, 2024 (the “Name ...

August 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch